Intestinal absorption and presystemic elimination of various chemical constituents present in GBE50 extract, a standardized extract of Ginkgo biloba leaves

Current Drug Metabolism

Volumn 13, Issue 5, 2012, Pages 494-509

  Li, Li ^a   Zhao, Yuansheng ^a,b   Du, Feifei ^a   Yang, Junling ^a   Xu, Fang ^a   Niu, Wei ^a   Ren, Yaohui ^a   Li, Chuan ^a,b  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

GBE50 extract; Ginkgo biloba; Intestinal absorption; Presystemic elimination

Indexed keywords

BIFLAVONE; CARBOXYLIC ACID; FLAVONE DERIVATIVE; FLAVONOL DERIVATIVE; GBE 50; GINKGO BILOBA EXTRACT; ISOFLAVONE; LACTONE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG ELIMINATION; DRUG SOLUBILITY; GINKGO BILOBA; INTESTINE ABSORPTION; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PLANT LEAF; RAT;

EID: 84861860594     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/1389200211209050494     Document Type: Article

References (74)

1. World Health organization. WHO Monographs on Selected Medicinal Plants; 1999, Volume 1, pp. 154-167. (http://apps.who.int/medicinedocs/en/d/Js2200e)
2. Blumenthal, M., Ed. The Complete German Commission E. Monographs: Therapeutic Guide to Herbal Medicines; American Botanical Council and Integrative Medicine Communications: Austin and Boston, 1998, pp. 136-138.
3. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China (English Edition 2005 Vol. I); People's Medical Publishing House: Beijing, 2005, pp. 322-323.
4. Blumenthal, M., Ed. The ABC Clinical Guide to Herbs; American Botanical Council: Austin, 2003, pp.185-200.
5. Mahadevan, S.; Park, Y. Multifaceted therapeutic benefits of Ginkgo biloba L.: chemistry, efficacy, safety, and uses. J. Food Sci., 2008, 73(1), R14-R19.
6. McKenna, D.J.; Jones, K.; Hughes, K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical application. Altern. Ther. Health Med., 2001, 7(5), 70-90.
7. Cai, D-S. Medicine Economic News, Sep. 24, 2010; B4.
8. Le Bars, P.L.; Katz, M.M.; Berman, N.; Itil, T.M.; Freedman, A.M.; Schatzberg, A.F. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA, 1997, 278(16), 1327-1332.
9. Ihl, R.; Bachinskaya, N.; Korczyn, A.D.; Vakhapova, V.; Tribanek, M.; Hoerr, R.; Napryeyenko, O. Efficacy and safety of a once-daily formulation of Ginkgo biloba extract EGb 761 in dementia with neuropsychiatric features: a randomized controlled trial. Int. J. Geriatr. Psychiatry, 2011, 26(11), 1186-1194.
10. Solomon, P.R.; Adams, F.; Silver, A.; Zimmer, J.; DeVeaux, R. Ginkgo for memory enhancement: a randomized controlled trial. JAMA, 2002, 288(7), 835-840.
11. DeKosky, S.T.; Williamson, J.D.; Fitzpatrick, A.L.; Kronmal, R.A.; Ives, D.G.; Saxton, J.A.; Lopez, O.L.; Burke, G.; Carlson, M.C.; Fried, L.P.; Kuller, L.H.; Robbins, J.A.; Tracy, R.P.; Woolard, N.F.; Dunn, L.; Snitz, B.E.; Nahin, R.L.; Furberg, C.D. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 2008, 300(19), 2253-2262.
12. Snitz, B.E.; O'Meara, E.S.; Carlson, M.C.; Arnold, A.M.; Ives, D.G.; Rapp, S.R.; Saxton, J.; Lopez, O.L.; Dunn, L.O.; Sink, K.M.; DeKosky, S.T. Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial. JAMA, 2009, 302(24), 2663-2670.
13. Wolsko, P.M.; Solondz, D.K.; Phillips, R.S.; Schachter, S.C.; Eisenberg, D.M. Lack of herbal supplement characterization in published randomized controlled trials. Am. J. Med., 2005, 118(10), 1087-1093.
14. Kressmann, S.; Biber, A.; Wonnemann, M.; Schug, B.; Blume, H.H.; Müller, W.E. Influence of pharmaceutical quality on the bioavailability of active components from Ginkgo biloba preparations. J. Pharm. Pharmacol., 2002, 54(11), 1507-1514.
15. van Beek, T.A., Ed. Ginkgo Biloba; Harwood Academic Publishers: Amsterdam, Netherlands, 2000.
16. van Beek, T.A.; Montoro, P. Chemical analysis and quality control of Ginkgo biloba leaves, extracts, and phytopharmaceuticals. J. Chromatogr. A, 2009, 1216 (11), 2002-2032.
17. Bhattaram, V.A.; Graefe, U.; Kohlert, C.; Veit, M.; Derendorf, H. Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine, 2002, 9(Suppl 3), 1-33.
18. Suehiro, M.; Simpson, N.R.; Underwood, M.D.; Castrillon, J.; Nakanishi, K.; van Heertum, R. In vivo biodistribution of ginkgolide B, a constituent of Ginkgo biloba, visualized by MicroPET. Planta Med., 2005, 71(7), 622-627.
19. Chen, W-D.; Liang, Y.; Xie, L.; Lu, T.; Liu, X-D.; Wang, G-J. Pharmacokinetics of the ginkgo B following intravenous administration of ginkgo B emulsion in rats. Biol. Pharm. Bull., 2007, 30(1), 1-5.
20. Xie, J-S.; Ding, C-G.; Ge, Q-H.; Zhou, Z.; Zhi, X-J. Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2008, 864(1-2), 87-94.
21. Ude, C.; Paulke, A.; Nöldner, M.; Schubert-Zsilavecz, M.; Wurglics, M. Plasma and Brain Levels of Terpene Trilactones in Rats after an Oral Single Dose of Standardized Ginkgo biloba Extract EGb 761®. Planta Med., 2010, 77(3), 259-264.
22. Rangel-Ordóñez, L.; Nöldner, M.; Schubert-Zsilavecz, M.; Wurglics, M. Plasma levels and distribution of flavonoids in rat brain after single and repeated doses of standardized Ginkgo biloba extract EGb 761®. Planta Med., 2010, 76(15), 1683-1690.
23. Liu, Y.; Liu, Y.; Dai, Y.; Xun, L-Y.; Hu, M. Enteric disposition and recycling of flavonoids and ginkgo flavonoids. J. Altern. Complement. Med., 2003, 9(5), 631-640.
24. Lu, T.; Yang, J-L.; Gao, X-M.; Chen, P.; Du, F-F.; Sun, Y.; Wang, F-Q.; Xu, F. ; Shang, H-C. ; Huang, Y-H.; Wang, Y.; Wan, R-Z.; Liu, C-X.; Zhang, B-L.; Li C. Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen), can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab. Dispos., 2008, 36(8), 1578-1586.
25. Liu, H-F.; Yang, J-L.; Du, F-F.; Gao, X-M.; Ma, X-T.; Huang, YH.; Xu, F.; Niu, W.; Wang, F-Q.; Mao, Y.; Sun, Y.; Lu, T.; Liu, CX.; Zhang, B-L.; Li C. Absorption and disposition of ginsenosides after oral administration of Panax notoginseng extract to rats. Drug Metab. Dispos., 2009, 37(12), 2290-2298.
26. Cech, N.B.; Enke, C.G. Practical implications of some recent studies in electrospray ionization fundamentals. Mass Spectrom. Rev., 2001, 20(6), 362-387.
27. Wang, L.; Sun, Y.; Du, F-F.; Niu, W.; Lu, T.; Kan, J-M.; Xu, F.; Yuan, K-H.; Qin, T.; Liu, C-X.; Li, C. 'LC-electrolyte effects' improve the bioanalytical performance of liquid chromatography/tandem mass spectrometric assays in supporting pharmacokinetic study for drug discovery. Rapid Commun. Mass. Spectrom., 2007, 21(16), 2573-2584.
28. Sun, Y.; Dai, J-Y.; Hu Z-Y.; Du F-F.; Niu, W.; Wang, F-Q.; Liu F.; Jin G-Z.; Li C. Oral bioavailability and brain penetration of (-)- stepholidine, a tetrahydroprotoberberine agonist at dopamine D1 and antagonist at D2 receptors, in rats. Br. J. Pharmacol., 2009, 158(5), 1302-1312.
29. Dai, J-Y.; Yang, J-L.; Li, C. Transport and metabolism of flavonoids from Chinese herbal remedy Xiaochaihu-tang across human intestinal Caco-2 cell monolayers. Acta Pharmacol. Sin., 2008, 29(9), 1086-1093.
30. Zhao, Y.H.; Le, J.; Abraham, M.H.; Hersey, A.; Eddershaw, P.J.; Luscombe, C.N.; Boutina, D.; Beck, G.; Sherborne, B.; Cooper, I.; Platts, J.A. Evaluation of human intestinal absorption data and subsequent derivation of a quantitative structure-activity relationship (QSAR) with the Abraham descriptors. J. Pharm. Sci., 2001, 90(6), 749-784.
31. Tetko, I.V.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl. P.; Palyulin, V.A.; Radchenko, E.V.; Zefirov, N.S.; Makarenko, A.S.; Tanchuk, V.Y.; Prokopenko, V.V. Virtual computational chemistry laboratory-design and description. J. Comput. Aid. Mol. Des., 2005, 19(6), 453-463.
32. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.
33. Veber, D.F.; Johnson, S.R.; Cheng, H.Y.; Smith, B.R.; Ward, K.W.; Kopple, K.D. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem., 2002, 45(12), 2615-2623.
34. Kronbach, T.; Mathys, D.; Umeno, M.; Gonzalez, F.J.; Meyer, U.A. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol. pharmacol., 1989, 36(1), 89-96.
35. Shen, H-W.; He, M-M.; Liu, H-F.; Wrighton, S.A.; Wang, L.; Guo, B.; Li C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos., 2007, 35(8), 1292-1300.
36. Wen, X.; Walle, T. Methylated flavonoids have greatly improved intestinal absorption and metabolic stability. Drug Metab. Dispos., 2006, 34(10), 1786-1792.
37. Zhu, B.T.; Patel, U.K.; Cai, M.X.; Conney, A.H. O-Methylation of tea polyphenols catalyzed by human placental cytosolic catechol- O-methyltransferase. Drug Metab. Dispos., 2000, 28(9), 1024-1230.
38. Lipinski, C.A. Drug-like prosperities and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods, 2000, 44(1): 235-249.
39. Thomas, V.H.; Bhattachar, S.; Hitchingham, L.; Zocharski, P.; Naath, M.; Surendran, N.; Stoner, C.; El-Kattan, A. The road map to oral bioavailability: an industrial perspective. Expert Opin. Drug Metab. Toxicol., 2006, 2(4), 591-608.
40. Hollman, P.C.H.; Katan, M.B. Absorption, metabolism, and bioavailability of flavonoids. In: Flavonoids in Health and Disease; Rice-Evans, C.A.; Pacher, L., Ed.; Marcel Dekker, Inc.: New York, USA, 1998, pp. 483-522.
41. Curatolo, W. Physical chemical properties of oral drug candidates in the discovery and exploratory development settings. Pharm. Sci. Tech. Today, 1998, 1(9), 387-393.
42. Amidon, G.L.; Lennernas, H.; Shah, V.P.; Crison, J.R. A theoretical basis for a biopharmaceutical classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res., 1995, 12(3), 413-420.
43. Yumoto, R.; Murakami, T.; Nakamoto, Y.; Hasegawa, R.; Nagai, J.; Takano, M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J. Pharmacol. Exp. Ther., 1999, 289(1), 149-155.
44. Liang, E.; Proudfoot, J.; Yazdanian, M. Mechanisms of transport and structure-permeability relationship of sulfasalazine and its snalogs in Caco-2 cell monolayers. Pharm. Res., 2000, 17(10), 1168-1174.
45. Xia, C-Q.; Liu, N.; Yang, D.; Miwa, G., Gan, L-S. Expression, localization, and functional characteristics of breast cancer resistance protein in caco-2 cells. Drug Metab. Dispos., 2005, 33(5), 637-643.
46. Sharom, F.J. The P-glycoprotein efflux pump: how does it transport drugs? J. Membr. Biol., 1997, 160(3), 161-175.
47. Leier, I.; Jedlitschky, G.; Buchholz, U.; Cole, S.P.; Deeley, R.G.; Keppler, D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugate. J. Biol. Chem., 1994, 269(45), 27807-27810.
48. Draper, M.P.; Martell, R.L.; Levy, S.B. Indomethacin-mediated reversal of multidrug resistance and drug efflux in human and murine cell lines overexpressing MRP, but not P-glycoprotein. Br. J. Cancer, 1997, 75(6), 810-815.
49. Shiozawa, K.; Oka, M.; Soda, H.; Yoshikawa, M.; Ikegami, Y.; Tsurutani, J.; Nakatomi, K.; Nakamura, Y.; Doi, S.; Kitazaki, T.; Mizuta, Y.; Murase, K.; Yoshida, H.; Ross, D.D.; Kohno, S. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic. Int. J. Cancer, 2004, 108(1), 146-151.
50. Walle, T. Absorption and metabolism of flavonoids. Free Radic. Bio. Med., 2004, 36(7), 829-837.
51. Manach, C.; Donovan, J.L. Pharmacokinetics and metabolism of dietary flavonoids in humans. Free Radic. Res., 2004, 38(8), 771-785.
52. van der Woude, H.; Boersma, H.; Vervoort, J.; Rietjens, I.M. Identification of 14 quercetin phase II mono- and mixed conjugates and their formation by rat and human phase II in vitro model systems. Chem. Res. Toxicol., 2004, 17(11), 1520-1530.
53. Zhang, L.; Zuo, Z.; Lin, G. Intestinal and hepatic glucuronidation of flavonoids. Mol. Pharm., 2007, 4(6), 833-845.
54. Barve, A.; Chen, C.; Hebbar, V.; Desiderio, J.; Saw C. L-L.; Kong, A-N. Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats. Biopharm. Drug Dispos., 2009, 30(7), 356-365.
55. Zamek-Gliszczynski, M.J.; Hoffmaster, K.A.; Nezasa, K-I.; Tallman, M.N.; Brouwer, K.L.R. Integration of hepatic drug transporters and phase II metabolizing enzymes: Mechanisms of hepatic excretion of sulfate, glucuronide, and glutathione metabolites. Eur. J. Pharm. Sci., 2006, 27(5), 447-486.
56. Chung, K.F.; Dent, G.; McCusker, M.; Guinot, P.; Page, C.P.; Barnes, P.J. Effect of a gingkolide mixture (BN 52063) in antagonizing skin and platelet responses to platelet activating factor in man. Lancet, 1987, 1(8527), 248-250.
57. Pietri, S.; Maurelli, E.; Drieu, K.; Culcasi, M. Cardioprotective and anti-oxidant effects of the terpenoid constituents of Ginkgo biloba extract (EGb 761). J. Mol. Cell Cardiol., 1997, 29(2), 733-742.
58. Ivic, L.; Sands, T.T.J.; Fishkin, N.; Nakanishi, K.; Kriegstein, A.R.; Strømgaard, K. Terpene trilactones from Ginkgo biloba are antagonists of cortical glycine and GABAA receptors. J. Biol. Chem., 2003, 278(40), 49279-49285.
59. Lv, H.; Wang, G.-J.; Wu, X.-L.; Xie, L.; Huang, C.-R.; Li, H.; Liang, Y.; Hao, H.-P.; Sun, J. Transport characteristics of ginkgolide B by Caco-2 cells and examination of ginkgolide B oral absorption potential using rat in situ intestinal loop method. Int. J. Pharm., 2008, 351(1-2), 31-35.
60. Madgula, V.L.M.; Avula, B.; Yu, Y.-B.; Wang, Y.-H.; Tchantchou, F.; Fisher, S.; Luo, W.; Khan, I.A.; Khan, S.I. Intestinal and bloodbrain barrier permeability of ginkgolides and bilobalides: in vitro and in vivo approaches. Planta Med., 2010, 76(6), 599-606.
61. Kleijnen, J.; Knipschild, P. Ginkgo biloba. Lancet, 1992, 340(8828), 1136-1139.
62. Biber, A. Pharmacokinetics of Ginkgo biloba extracts. Pharmacopsychiatry, 2003, 36(Suppl 1), S32-S37.
63. Noon, J-H.; Tsushida, T.; Nakahara, K.; Terao, J. Identification of quercetin 3-O-β-D-glucuronide as an antioxidative metabolite in rat plasma after oral administration of quercetin. Free Rad. Bio. Med., 2001, 30(11), 1274-1285.
64. Day, A.J.; Gee, J.M.; DuPont, M.S.; Johnson, I.T.; Johnson, I.T.; Williamson G. Absorption of quercetin-3-glucoside and quercetin- 4'-glucosidise in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem. Pharmacol., 2003, 65(7)1199-1206.
65. Graf, B.A.; Ameho, C.; Dolnikowski, G.G.; Milbury, P.E.; Chen CY.; Blumberg, J.B. Rat gastrointestinal tissues metabolize quercetin. J. Nutr., 2006, 136(1), 39-44.
66. Nemeth, K.; Piskula, M.K. Food content, processing, absorption and metabolism of onion flavonoids. Cri. Rev. Food Sci. Nutr., 2007, 47(4), 397-409.
67. Mullen, W.; Edwards, C.A.; Crozier, A. Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulphoconjugates of quercetin in human plasma and urine after ingestion of onions. Br. J. Nutr., 2006, 96(1), 107-116.
68. Mullen, W.; Graf, B.A.; Caldwell, S.T.; Hartley, R.C.; Duthie, G.G.; Edwards, C.A.; Lean, M.E.; Crozier, A. Determination of flavonol metabolites in plasma and tissues of rats by HPLCradiocounting and tandem mass spectrometry following oral ingestion of [2-(14)C]quercetin-4'-glucoside. J. Agric. Food Chem., 2002, 50(23), 6902-6909.
69. Németh, K.; Plumb, G.W.; Berrin, J.G.; Juge, N.; Jacob, R.; Naim, H.Y.; Williamson, G.; Swallow, D.M.; Kroon, P.A. Deglycosylation by small intestinal epithelial cell beta-glucosidases is a critical step in the absorption and metabolism of dietary flavonoid glycosides in humans. Eur. J. Nutr., 2003, 42(1), 29-42.
70. Arts, I.C.; Sesink, A.L.; Faassen-Peters, M.; Hollman, P.C. The type of sugar moiety is a major determinant of the small intestinal uptake and subsequent biliary excretion of dietary quercetin glycosides. Br. J. Nutr., 2004, 91(6), 841-847.
71. Simons, A.L.; Renouf, M.; Hendrich, S.; Murphy, P.A. Human gut microbial degradation of flavonoids: structure-function relationships. J. Agric. Food Chem., 2005, 53(10), 4258-4263.
72. Saponara, R.; Bosisio, E. Inhibition of cAMP-phosphodiesterase by biflavones of Ginkgo biloba in rat adipose tissue. J. Nat. Prod., 1998, 61(11), 1386-1387.
73. Dell'Agli, M.; Bosisio, E. Biflavones of Ginkgo biloba stimulate lipolysis in 3T3-L1 adipocytes. Planta Med., 2002, 68(1), 76-79.
74. Dell'Agli, M.; Galli, G.V.; Bosisio, E. Inhibition of cGMPphosphodiesterase- 5 by biflavones of Ginkgo biloba. Planta Med., 2006, 72(5), 468-470.